Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Mirum Pharmaceuticals Submits Supplemental New Drug Application for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
Mirum Pharmaceuticals has announced that it has submitted a supplemental New Drug Application (sNDA) for […]
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called […]
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
Pfizer has announced that the United States Food and Drug Administration (FDA) approved its supplemental […]
U.S. FDA Grants Regular Approval for Jemperli for the Treatment of Patients with Recurrent or Advanced Mismatch Repair-deficient Endometrial Cancer
GSK reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) […]
FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the […]
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
Rocket Pharmaceuticals, a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic […]
Sandoz Biologics License Application for Proposed Biosimilar Denosumab Accepted by US FDA
Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the US […]
Egret Therapeutics Receives FDA Clearance of IND Application for EGT 101 for Treatment of Delayed Cerebral Ischemia
Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, has […]
Orexo Submits New Drug Application to FDA for OX124, a High-dose Rescue Medication for Opioid Overdose
Orexo AB announces the submission of a New Drug Application (NDA) to the US Food and […]
RefleXion Receives FDA Clearance for Biology-Guided Radiotherapy Treatment for Early and Late-stage Cancers
RefleXion Medical, a therapeutic oncology company, today announced the US Food and Drug Administration (FDA) […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more